US FDA to study safety of widely used abortion pill
Synopsis
The FDA has started a new review of mifepristone safety data, bringing renewed attention to the abortion medication used in most U.S. abortions. The study comes amid ongoing legal disputes over telehealth prescribing and mail delivery, with healthcare providers and policymakers closely watching the outcome.
FDA begins anew its study of the safety of Mifepristone as medication abortion remains a key element in the US healthcare debate.
A new study to be performed will look at the safety data regarding the medication used for most US abortions while continuing litigation regarding its access in courts and legislatures throughout states. On June 5, reports indicated that the US Food and Drug Administration had commenced another study to investigate the safety profile of the abortion medication, Mifepristone.
The drug is used for the majority of medicated abortions carried out in the US, and the new study will analyze the relevant adverse event reports and other data the FDA has acquired through its monitoring systems. The preliminary findings are expected sometime later this year.
The fact that this new review is underway places the focus squarely on a drug that has become one of the most debated subjects in American healthcare and regulatory law. Mifepristone received approval by the FDA in the year 2000, and is typically used with Misoprostol to perform an early termination.
The FDA has consistently maintained that Mifepristone has a strong safety record supported by decades of use.
The timeliness of this review should not be lost, because medicated abortions now constitute the majority of abortions in the United States. The most recent data indicate that in 2023, clinician-provided abortions made up around 63% of those conducted throughout the country, a figure derived from data provided by the Guttmacher Institute. This means that pharmacy, not physician access, has become a significant factor in reproductive healthcare.
Healthcare providers, pharmaceutical manufacturers, insurers and telehealth providers await the outcome of the review amid ongoing court battles concerning rules about prescribing and delivery of the medication; courts have been deciding cases concerning the legality of mail-order delivery and remote prescribing of Mifepristone. These decisions impact all stakeholders and have implications for health care access and digital health.
Mifepristone is not exclusive to the United States; it is legal in Australia, Canada, the United Kingdom, France, Germany, New Zealand, and numerous other nations.
In Australia it is obtainable through health care providers or approved telehealth services, which means developments regarding US legislation are relevant to lawmakers, health care industries and pharmaceutical manufacturers everywhere.
The FDA has stated that they will not alter any current laws as part of the study, and that this study is only concerned with evaluating the available data regarding the safety of the drug.
Follow Inspirepreneur Magazine for daily global business news.
Pooja Malik is a business journalist with over six years of experience covering startups, entrepreneurship, and emerging trends. She has previously worked with leading media platforms such as YourStory Media and BW BusinessWorld, where she reported on business, policy, and market developments. Currently, she serves as Editor at The Inspirepreneur Magazine, where she writes and edits stories across business, lifestyle, and travel, with a focus on clarity, accuracy, and reader relevance.
